Last updated: July 30, 2026

Clindamycin phosphate is a long-established, off-patent antibiotic whose US revenue trajectory is dominated by generic supply, payer pricing pressure, and formulation-level competition across topical, vaginal, and injectable segments. The market is fragmented, with recurring entry risk from ANDA filers and sustained discounting that compresses unit economics, particularly where multiple therapeutically equivalent products compete.

What is the current US market size for clindamycin phosphate and how is demand trending?

Featured snippet: Demand for clindamycin phosphate is steady-to-declining in real terms, with growth capped by generic competition and substitution toward formulary-favored antibiotic classes; volume is maintained by persistent indications in acne/skin infections, bacterial vaginosis, and certain dental and surgical prophylaxis/off-label uses.

Clindamycin phosphate is marketed in multiple dosage forms and routes:

Topical (eg, clindamycin phosphate gel/solution/foam, used for acne vulgaris)
Vaginal (eg, clindamycin phosphate vaginal cream, used for bacterial vaginosis)
Oral (historically) (clindamycin hydrochloride has seen more branded presence; “clindamycin phosphate” is less prominent in oral branded product lines)
Injectable (clindamycin phosphate IV used in serious anaerobic infections, perioperative settings, and special populations)

Segment dynamics that shape revenue

Top-line sales move with three factors:

Formulary access and substitution
Generic clindamycin phosphate products compete heavily under pharmacy benefit management. This limits pricing power and creates “winner takes more volume” dynamics at the NDC level rather than across the molecule.
Antibiotic stewardship
Use of clindamycin is constrained by evolving prescribing patterns. In many settings, clinicians substitute against resistance patterns, local antibiograms, and guideline updates.
Supply stability and manufacturing yield
The antibiotic manufacturing supply chain can cause short-lived price swings when a facility exits or a quality event triggers backorders. Over multiple years, however, generic competition returns to baseline price compression.

How do pricing and payer contracting dynamics affect clindamycin phosphate revenue?

Featured snippet: Revenue is primarily driven by wholesale acquisition price-to-net price compression and by payer contracting for generic NDCs, where net prices track competitive bids more than list price.

Key pricing mechanisms in generic antibiotics

Net price compression due to PBM preferred formulary tiers.
Channel inventory behavior where distributors accelerate turns for fast-moving NDCs, tightening margin volatility.
Short-cycle rebate recalibration as new ANDA entries land and wholesalers rebalance shelf inventory.

What changes unit economics in practice

Contract status of specific NDCs: identical label content, different manufacturer NDCs can show materially different realized revenue due to contracting.
DAW vs interchangeability: clindamycin phosphate is routinely substitutable with therapeutically equivalent generics, limiting brand-like pricing behavior.
Mix shift: growth in one segment (eg, topical for acne) does not automatically translate into aggregate revenue gains if the segment’s pricing declines faster than volume rises.

Which dosage forms drive the financial trajectory of clindamycin phosphate?

Featured snippet: Injectable clindamycin phosphate has episodic demand linked to inpatient prescribing patterns; topical and vaginal formulations are steadier but price-compressed by multiple generics and brand-absence economics.

Injectable (IV clindamycin phosphate)

Typically tracks hospital formularies and infection service protocols.
Exposed to drug supply disruptions and contract bid cycles for group purchasing organization (GPO) tenders.
Revenue tends to be less sensitive to seasonality than outpatient topical products, but sensitive to inpatient case mix and antibiotic utilization policies.

Topical clindamycin phosphate (acne)

Driven by dermatologist and primary care prescribing.
Outpatient generic market dynamics yield consistent volume with sustained margin pressure.
Competitive substitutions can shift to other topical antibiotics and combination regimens (eg, with benzoyl peroxide or retinoids), depending on guideline alignment and tolerability.

Vaginal clindamycin phosphate (bacterial vaginosis)

More constrained “indication-specific” prescribing and distribution channels.
Revenue stability depends on repeat treatment patterns, prescriber preferences, and competitive availability.

What patents protect clindamycin phosphate, and when do exclusivities expire?

Featured snippet: The active ingredient clindamycin phosphate is widely off exclusivity; most market protection is not active-ingredient exclusivity but rather formulation-specific, manufacturing-process, and label/packaging IP, many of which expire or are effectively irrelevant for generic block.

Practical view for market entry and litigation

For clindamycin phosphate, the relevant IP risk tends to be:

ANDA litigation history for specific NDCs (not usually for the molecule universally).
Case-by-case formulation patents tied to a specific dosage form strength, release characteristics, or manufacturing method.

Because the product is mature and generic-dominant, financial trajectory is more affected by:

the availability and cost of supply,
contracting and substitution, and
new ANDA entries, than by any remaining broad patent estate for clindamycin phosphate itself.

How does ANDA/Paragraph IV litigation risk affect generic entry for clindamycin phosphate?

Featured snippet: Generic entry risk is ongoing at the NDC level, but the overall market is already populated with multiple ANDA products, so litigation has limited ability to create long-term pricing power for any single seller.

What typically drives litigation for older antibiotics

Patent challenges to formulation or manufacturing patents listed in Orange Book for specific strengths/forms.
Settlement agreements that can result in delayed launches or co-existence under license.

Commercial impact channel

Even where launches are delayed, net revenue dynamics often remain pressured because:

alternative NDCs inside the same molecule and form can be substituted,
competitors adjust contracting bids, and
wholesalers diversify across suppliers.

What is the Orange Book status of clindamycin phosphate products?

Featured snippet: Orange Book listings for clindamycin phosphate are dominated by generic-era listings and expired ingredient patents; current status typically shows few, narrow, product-specific remaining protections.

How Orange Book status translates into pricing

Where listed patents have expired or are not enforceable against the generic at issue, competitive entry accelerates.
Where a settlement controls specific NDCs, the market can see short-term pricing stabilization for the covered product, then normalization after the restricted launch window ends.

How strong is the patent estate for clindamycin phosphate and what is the commercial implication?

Featured snippet: The patent estate for clindamycin phosphate is not a structural barrier to generic competition; commercial implications are dominated by manufacturing cost curves and contracting rather than by sustained exclusivity.

Patent estate drivers

Narrow, dosage-form-specific IP tends to fragment protection.
Portfolio overlap across companies rarely prevents market-wide generic substitution.

Bottom line for financial trajectory

Expect low brand-like margin behavior and persistent price competition.
Company differentiation comes from supply reliability, contracting reach, and execution quality, not from IP moats at the molecule level.

Which companies compete in clindamycin phosphate and how is the competitive landscape evolving?

Featured snippet: Competition is largely between generic manufacturers and distributors; ongoing entries and tender wins decide market share more than product innovation.

Competitive posture that matters commercially

Hospital/GPO tender presence for IV formulations.
Retail pharmacy PBM contracting for topical and vaginal products.
NDC portfolio breadth across strengths and packaging sizes.

What to watch for in market share shifts

Manufacturing capacity expansions that unlock supply for key tenders.
Quality events that remove specific NDCs from the market, creating temporary price premiums that fade once supply returns.
Rebate renegotiations triggered by new generic launches.

How do settlement agreements and licensing deals influence clindamycin phosphate revenue?

Featured snippet: Settlement-driven “launch timing” can temporarily stabilize pricing for specific NDCs, but it rarely changes long-term financial trajectory because multiple competing suppliers remain active and substitutable.

Typical commercial outcomes

Delayed entry of a challenger can protect an existing supplier’s share for a finite period.
Licensed co-marketing can maintain category supply but with reduced per-unit margins for all participants once new competition begins.
Scope-limited coverage: settlements often apply to a specific dosage form/strength/patent combination, leaving other NDCs exposed.

When does clindamycin phosphate lose exclusivity and what does that mean for forecasts?

Featured snippet: For most clindamycin phosphate NDCs, exclusivity is already lost; forecast sensitivity comes mainly from new ANDA launches, not from a molecule-wide exclusivity countdown.

Forecast implications

Model revenue with:
- unit volume stability (prescribing persistence),
- net price drift down with each meaningful entry,
- margin swings tied to supply disruptions and tender resets.

How does clindamycin phosphate compare with other antibiotics used for similar indications?

Featured snippet: Therapeutic substitution is common across antibiotic classes, so net category share depends on local guideline preference and formulary tiering rather than clindamycin-specific brand strength.

Cross-class competitive factors

Resistance and guideline updates can redirect prescribing.
Combination regimen preferences in acne can reduce monotherapy clindamycin share.
BV management patterns influence vaginal clindamycin utilization versus alternative BV regimens.

What generic entry risks exist for clindamycin phosphate by route and formulation?

Featured snippet: Entry risks are highest where a specific dosage form/strength has fewer suppliers or where a tender favored one supplier for a period; otherwise, the category is already highly genericized.

Injectable risk profile

Multiple generic suppliers already exist in most markets; new entry risk mainly impacts pricing and tender competitiveness, not market existence.

Topical risk profile

NDC-level competition across vehicles and pack sizes can shift rapidly.
Premium pricing is generally unsustainable once PBM contracting broadens.

Vaginal risk profile

Specialist prescribing patterns can protect volume, but the generic category limits price durability.

What are the key financial KPIs to track for clindamycin phosphate companies?

Featured snippet: Track NDC-level net sales, tender wins, and gross-to-net compression; adjust for supply events and new supplier entries.

KPI set

Net sales by dosage form (IV, topical, vaginal)
Gross-to-net ratio changes with rebate/contract renegotiations
Share-of-shelf proxy via distributor listings and tender allotments
Backorder frequency as a leading indicator of revenue volatility
NDC count and portfolio mix to detect erosion from new entrants

Key Takeaways

Clindamycin phosphate’s financial trajectory is shaped by generic competition, payer contracting, and supply dynamics, not by remaining molecule-level exclusivity.
Revenue trends tend to show volume resilience with persistent net price compression and margin pressure across injectable, topical, and vaginal segments.
Litigation and Orange Book protections are typically NDC-specific and narrow, so they rarely prevent long-term price normalization once additional ANDA launches occur.
Competitive advantage is operational: tender execution, manufacturing reliability, and NDC portfolio breadth.

FAQs

1) Why do clindamycin phosphate net prices keep falling even when demand is stable?
Generic substitution and PBM/GPO contracting reset net prices downward as new NDCs enter and preferred tiers rotate.

2) Does clindamycin phosphate have meaningful biosimilar risk?
No. Clindamycin phosphate is a small-molecule antibiotic; biosimilar frameworks do not apply.

3) Which channel drives the most volatility for injectable clindamycin phosphate?
Hospital procurement cycles and supply disruptions tied to manufacturing quality or capacity constraints.

4) Can formulation changes protect clindamycin phosphate revenue?
Only at the NDC level and only for limited periods if formulation-specific IP remains enforceable against generic manufacturing and marketing.

5) What is the most realistic forecast assumption for clindamycin phosphate over the next 3–5 years?
Steady-to-slight volume changes with ongoing net price compression, moderated by supply stability and tender outcomes.

References

FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Food and Drug Administration. “Drugs@FDA.” https://www.accessdata.fda.gov/scripts/cder/daf/
FDA. “ANDA Approval: Generic Drug Information.” U.S. Food and Drug Administration. https://www.fda.gov/drugs/generic-drugs/and a-approval-generic-drug-information

International Patents:	36
US Patents:	3
Tradenames:	18
Applicants:	50
NDAs:	94
Drug Master File Entries:	25
Finished Product Suppliers / Packagers:	37
Raw Ingredient (Bulk) Api Vendors:	72
Clinical Trials:	33
Patent Applications:	4,149
Drug Prices:	Drug price trends for CLINDAMYCIN PHOSPHATE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CLINDAMYCIN PHOSPHATE
What excipients (inactive ingredients) are in CLINDAMYCIN PHOSPHATE?	CLINDAMYCIN PHOSPHATE excipients list
DailyMed Link:	CLINDAMYCIN PHOSPHATE at DailyMed

Sponsor	Phase
Sun Pharmaceutical Industries, Inc.	PHASE1
Ain Shams Maternity Hospital	NA
Shehab Ahmed Hamad	PHASE3

Drug Class	Lincosamide Antibacterial
Physiological Effect	Decreased Sebaceous Gland Activity Neuromuscular Blockade

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal	CLINDAMYCIN PHOSPHATE	clindamycin phosphate	GEL;TOPICAL	214668-001	Aug 5, 2022	AB2	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Rising	CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER	clindamycin phosphate	INJECTABLE;INJECTION	203048-002	Apr 4, 2013	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Encube	CLINDAMYCIN PHOSPHATE	clindamycin phosphate	GEL;TOPICAL	212438-001	Mar 11, 2021	AB1	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Pfizer	CLEOCIN	clindamycin phosphate	SWAB;TOPICAL	050537-002	Feb 22, 1994		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Fougera Pharms	CLINDAMYCIN PHOSPHATE	clindamycin phosphate	LOTION;TOPICAL	065067-001	Jan 31, 2002	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Padagis Us	CLINDAMYCIN PHOSPHATE	clindamycin phosphate	SWAB;TOPICAL	065049-001	May 25, 2000	AT	RX	No	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Hikma	CLINDAMYCIN PHOSPHATE	clindamycin phosphate	INJECTABLE;INJECTION	062953-001	Apr 21, 1988		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	CLINDAGEL	clindamycin phosphate	GEL;TOPICAL	050782-001	Nov 27, 2000	6,387,383	⤷ Start Trial
Norvium Bioscience	EVOCLIN	clindamycin phosphate	AEROSOL, FOAM;TOPICAL	050801-001	Oct 22, 2004	7,141,237	⤷ Start Trial
Padagis Us	CLINDESSE	clindamycin phosphate	CREAM;VAGINAL	050793-001	Nov 30, 2004	5,266,329	⤷ Start Trial
Padagis Us	CLINDESSE	clindamycin phosphate	CREAM;VAGINAL	050793-001	Nov 30, 2004	6,899,890	⤷ Start Trial
Padagis Us	CLINDESSE	clindamycin phosphate	CREAM;VAGINAL	050793-001	Nov 30, 2004	5,993,856	⤷ Start Trial
Pfizer	CLEOCIN	clindamycin phosphate	SUPPOSITORY;VAGINAL	050767-001	Aug 13, 1999	6,495,157	⤷ Start Trial
Norvium Bioscience	EVOCLIN	clindamycin phosphate	AEROSOL, FOAM;TOPICAL	050801-001	Oct 22, 2004	7,374,747	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Country	Patent Number	Title	Estimated Expiration
Canada	2993012	FORMULATIONS ET TRAITEMENTS TOPIQUES (TOPICAL FORMULATIONS AND TREATMENTS)	⤷ Start Trial
Canada	3209380	FORMULATIONS ET TRAITEMENTS TOPIQUES (TOPICAL FORMULATIONS AND TREATMENTS)	⤷ Start Trial
Canada	3298548	TOPICAL FORMULATIONS AND TREATMENTS	⤷ Start Trial
Denmark	3324938		⤷ Start Trial
European Patent Office	3324938	FORMULATIONS ET TRAITEMENTS TOPIQUES (TOPICAL FORMULATIONS AND TREATMENTS)	⤷ Start Trial
Spain	2891754		⤷ Start Trial
Hungary	E056401		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1304992	C01304992/01	Switzerland	⤷ Start Trial	PRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
1304992	C300617	Netherlands	⤷ Start Trial	PRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
1304992	PA2013025,C1304992	Lithuania	⤷ Start Trial	PRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
1304992	CR 2013 00053	Denmark	⤷ Start Trial	PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
1304992	2013/044	Ireland	⤷ Start Trial	PRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
1304992	SPC/GB13/061	United Kingdom	⤷ Start Trial	PRODUCT NAME: CLINDAMYCIN PHOSPHATE IN COMBINATION WITH TRETINOIN.; REGISTERED: IE PA1332/043/001 20130322; UK PL15142/0249 20130624
1304992	122013000081	Germany	⤷ Start Trial	PRODUCT NAME: CLINDAMYCIN (ALS CLINDAMYCIN-PHOSPHAT) UND TRETINOIN; NAT. REGISTRATION NO/DATE: 85210.00.00 20130611; FIRST REGISTRATION: IRLAND PA1332/043/001 20130322
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Summary for CLINDAMYCIN PHOSPHATE

Recent Clinical Trials for CLINDAMYCIN PHOSPHATE

Pharmacology for CLINDAMYCIN PHOSPHATE

Anatomical Therapeutic Chemical (ATC) Classes for CLINDAMYCIN PHOSPHATE

Paragraph IV (Patent) Challenges for CLINDAMYCIN PHOSPHATE